KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Share-based Compensation (2018 - 2025)

Adaptive Biotechnologies (ADPT) has disclosed Share-based Compensation for 8 consecutive years, with $12.7 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation fell 0.87% to $12.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $51.5 million through Dec 2025, down 3.97% year-over-year, with the annual reading at $51.5 million for FY2025, 3.97% down from the prior year.
  • Share-based Compensation hit $12.7 million in Q4 2025 for Adaptive Biotechnologies, down from $13.3 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $17.3 million in Q2 2023 to a low of $8.5 million in Q1 2021.
  • Historically, Share-based Compensation has averaged $13.3 million across 5 years, with a median of $13.3 million in 2025.
  • Biggest five-year swings in Share-based Compensation: soared 81.48% in 2021 and later decreased 25.29% in 2024.
  • Year by year, Share-based Compensation stood at $11.9 million in 2021, then increased by 20.37% to $14.3 million in 2022, then grew by 8.83% to $15.6 million in 2023, then decreased by 17.51% to $12.8 million in 2024, then dropped by 0.87% to $12.7 million in 2025.
  • Business Quant data shows Share-based Compensation for ADPT at $12.7 million in Q4 2025, $13.3 million in Q3 2025, and $13.4 million in Q2 2025.